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Abstract: Proteoglycans are important components of the extracellular matrix of all tissues. Proteoglycans are comprised 
of a core protein and one or more covalently attached glycosaminoglycan (GAG) chains. The major chondroitin sulfate 
(CS) and dermatan sulfate (DS) proteoglycans are aggrecan, versican, biglycan and decorin. Cells synthesize GAGs of 
natural or basal lengths and the GAG chains are subject to considerable growth factor, hormonal and metabolic regulation 
to yield longer GAG chains with altered structure and function. The mechanism by which the CS/DS GAG chains are po-
lymerized is unknown. Recent work has identified several monosaccharide transferases which when co-expressed yield 
GAG polymers and the length of the polymers depends upon the pair of enzymes coexpressed. The further extension of 
these chains is regulated by signaling pathways. Inhibition of these latter pathways may be a therapeutic target to prevent 
the elongation which is associated with increased binding of atherogenic lipids and the disease process of atherosclerosis. 
Keywords: Proteoglycans, chondroitin sulfate, glycosaminoglycans, enzymology, polymerases, signaling. 
1. INTRODUCTION 
  Proteoglycans are an integral part of the extracellular   
matrix of all tissues [1]. In some tissues proteoglycans are a  
low component by mass but are highly important because  
they are both structural molecules and actively involved in  
critical cell functions including proliferation, migration, phe- 
notypic expression and secretion [2]. Proteoglycans are   
complex macromolecules comprised of a core protein and   
one or more covalently attached glycosaminoglycans (GAG)  
chains so that structurally they are both proteins and carbo- 
hydrates. The spectrum of properties of proteoglycans is   
determined by both the core proteins and the GAG chains.  
Core proteins determine the cellular location and serve as   
scaffolds for the GAG chains and the highly ionic chains   
determine physical properties of tissues and bind factors in- 
cluding growth factors and apolipoproteins. The complemen- 
tary roles of core protein and GAG are exemplified by the  
observation that binding of Low Density Lipoproteins (LDL)  
to GAG chains of intact proteoglycans occurs with an order  
of magnitude higher affinity than the binding to free GAG  
chains [3]. There is considerable interest in the biosynthetic  
pathways determining proteoglycan and particularly GAG   
structure because GAG chains are implicated in many fun- 
damental biological and pathological processes [4]. The sig- 
naling pathways regulating core protein synthesis and GAG  
elongation are of specific interest. The pathways regulating  
these two processes are distinct with initial evidence indicat- 
ing that the signaling pathway regulating core protein ex- 
pression is aligned to that of the cell cycle whereas the 
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signaling pathway regulating elongation of GAGs has some 
distinct properties [5]. The biochemical mechanisms and 
signaling pathways regulating the synthesis of GAG chains 
are the focus of this review.  
  The GAG chains consisting of a tetrasaccharide linkage 
region and repeating disaccharide moieties are sulfated ga-
lactosaminoglycans in the case of chondroitin sulfate (CS) 
and dermatan sulfate (DS) proteoglycans. CS and DS GAGs 
are initially synthesized as CS GAGs (containing glucuronic 
acid (GlcA)) and the activity of the enzyme C5-epimerase to 
isomerize GlcA to Iduronic acid (IdoA) by definition gener-
ates DS GAGs [6]. Thus this review refers to CS GAG syn-
thesis but the discussion, allowing for the action of 
C5-epimerase, also relates to DS GAG chains. The major CS 
proteoglycans are aggrecan, which forms a substantial struc-
tural component of cartilage and is composed of both CS and 
keratan sulfate GAG chains, and the large CS proteoglycan 
versican which is prominent in blood vessels. The smaller 
leucine-rich proteoglycans, biglycan and decorin, are CS 
GAG with some epimerase modification rendering them DS 
proteoglycans and they are also prominently expressed in 
blood vessels [7]. The highly ionized state of the sulfated 
GAG chains leads to their role in determining the physical 
properties of tissues such as the resistance to compression of 
cartilage provided by aggrecan. The loss of CS from carti-
lage is a major cause of osteoarthritis [8]. Conversely, the 
accumulation of biglycan in the wall of injured blood vessels 
leads to the trapping of apolipoproteins and is recognized as 
the initiating factor in atherosclerosis which underlies most 
cardiovascular disease [9, 10]. 
  Although GAGs have critical biological roles the precise 
mechanism by which CS GAG polymers are synthesized is 
unknown. Until recently, no in vitro system has proven ca-
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secreted by cells and occurring in tissues. GAG chains do 
not have a discrete molecular weight but rather have a spec-
trum of values which can be readily observed by SDS-PAGE 
(see Fig. (1) Lower Panel) or size exclusion analysis plots 
[11]. The range of normal GAG chain lengths is very wide 
and extends from 20 to approximately 60 KDa correspond-
ing to approximately 40-120 disaccharides. Proteoglycans, 
such as biglycan, have endogenous synthesis and superim-
posed upon it the phenomena of GAG hyperelongation. In 
this response, agonists, such as hormones and growth factors 
stimulate signaling pathways leading to elongation and thus 
an increase in the average molecular weight [12, 13] (see 
Fig. 1). Growth factor signaling pathways can also alter epi-
merization and the disaccharide sulfation pattern and all 
these structural alterations are considered to have functional 
consequences [14].  
  This article addresses the question of whether the hypere-
longation effect is an extension of or is distinct from the ba-
sic GAG chain polymerizing process. To relate structure to 
function we use the example of the binding of CS/DS GAG 
chains to apolipoproteins on lipids and the GAG structural 
features affecting this interaction [15]. We further consider if 
it may be possible to dissect the basic mechanisms of GAG 
synthesis associated with the physiological roles of these 
molecules, from the mechanisms of hyperelongation that 
represent a target for the prevention of lipid retention dis-
eases such as atherosclerosis and calcific aortic valve disease 
(CAVD) [14, 16, 17]. 
2. BIOCHEMISTRY OF GAG SYNTHESIS 
  CS/DS GAGs on proteoglycans are synthesized by the 
initial addition of a xylose (Xyl) residue to a specific serine 
in the core protein followed by the sequential addition of two 
galactose (Gal) and one GlcA residues to form the tetrasac-
charide linkage region (GlcA1-3Gal1-3Gal1-4Xyl1-O-
Ser) [18] (see Fig. 1). The Xyl and Gal residues in this re-
gion can be modified by phosphorylation and sulfation and 
these modifications have a profound influence on subsequent 
GAG chain synthesis [19]. Transfer of a GalNAc residue to 
the terminal GlcA of the linkage region initiates chain po-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Schema and actual experimental depiction of the structure of “natural” and “hyperelongated” chondroitin and dermatan sulfate gly-
cosaminoglycan (GAG) chains. Natural or basal GAG chains are defined in the text and the hyperelongation of GAG chains (as indicated in 
the figure – Upper Panel) occurs, for example, when vascular smooth muscle cells are stimulated with growth factors such as TGF. The 
electrophoretic mobility of intact 
35S-SO4 labeled proteoglycans can be assessed by SDS-PAGE (4-20 % acrylamide gradient gel) using a 
fixed amount of radioactivity per lane. The SDS-PAGE gel of the biglycan produced and secreted by vascular smooth muscle cells treated 
with various concentrations of TGF for 24 h is shown (Lower Panel) where the decreasing migration of the biglycan band with increasing 
TGF occurs due to the lengthening of the GAG chains (see text for references). In the context of the current paper, the band in lane 2 (sec-
ond from left) is natural or basal biglycan and the bands in lanes 3 to 9 are hyperelongated biglycan derived from cells treated with TGF or 
PDGF (platelet-derived growth factor). See text and references therein for further details. 
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lymerization and thus the sequential alternate transfer of 
GalNAc and GlcA forms the disaccharide repeat units of the 
polymerizing GAG chain. The GAG chain is subject to sul-
fation and epimerization to yield further structural heteroge-
neity [18]. Whereas the core protein has a defined molecular 
weight derived from its mRNA coding and amino acid struc-
ture, the GAG chains have a range of sizes conferring a 
range of molecular weights to the whole proteoglycan. Ap-
proximately 15 enzymes have been cloned which undertake 
these steps of linkage region and CS GAG synthesis but the 
manner in which they affect GAG polymerization is un-
known [18]. 
  A further important consideration of GAG chain structure 
in tissues is that numerous factors can stimulate cells to pro-
duce modified, particularly elongated GAG chains, which 
we term hyperelongated GAGs [10, 16]. Although the out-
come of cell stimulation leading to modification of CS 
GAGs is clearly established, only in the last decade have the 
signaling pathways begun to be defined and nothing is 
known of the link between the signaling pathways and the 
precise biochemical modifications that lead to the changes in 
GAG structure. 
3. ENZYMES REGULATING THE SYNTHESIS OF CS 
GAG CHAINS 
  GAG chain initiation and attachment to the core protein 
occurs principally within the linked compartments of the 
endoplasmic reticulum (ER) and the cis and trans Golgi. CS, 
DS and heparan sulfate (HS) GAG chains are attached to 
serine residues of core proteins via an O-linked glycosidic 
bond. A single consensus sequence for GAG chain initiation 
has not been defined although serine residues flanked by 
glycine appear to be involved [18]. A tetra-saccharide link-
age region is initiated by the action of the enzyme UDP-Xyl 
transferase to attach the pentose sugar, Xyl, to a serine resi-
due on the core protein [20]. Addition of the linker region 
occurs in a compartment intermediate to the endoplasmic 
reticulum and the Golgi apparatus [1]. Construction of the 
tetrasaccharide linkage region continues with the addition of 
two galactose (Gal) units by UDP-Gal transferase I and II 
respectively and is completed upon addition of GlcA by 
UDP-GlcA transferase I [21]. The addition of characteristic 
repeating disaccharide units differs at this point which is a 
divergence point for the biosynthesis of different types of 
GAG chains. Intriguingly, modifications including sulfation 
and phosphorylation of the tetrasaccharide linkage region 
may influence the resultant GAG types [19, 22, 23].  
  Multiple enzymes involved in the sequential addition of 
monosaccharides, have been identified, cloned and their 
transferase and polymerase activities characterized [24-29]. 
GalNAc transferase I and II and GlcA transferase II are in-
volved in CS biosynthesis and the enzyme C-5 GlcA epime-
rase converts CS to DS. For comparison, for heparin and HS 
synthesis the enzymes EXTL2, EXT1, EXT2, several 
NDSTs and C-5 GlcA epimerase have been identified [21]. 
Sulfation of the GAG chains also occurs in the Golgi appara-
tus, where sulfotransferases add sulfate groups from 
3’phosphoadenosine-5’phosphosulfate (PAPS) to specific 
positions on the emerging polysaccharide chain [30]. 
4. TRANSFERASES, POLYMERASES AND THE DE-
TERMINATION OF “NATURAL” GAG LENGTH 
  The “natural” length of GAG chains is defined as the 
length of GAG chain synthesized by the GAG elongation 
machinery operating in a cell which is not stimulated by ex-
ternal stimuli which cause additional elongation of GAG 
chain length [16] (see Fig. (1) for schematic representation). 
Presently six homologous enzymes have been cloned which 
can undertake the addition of a monosaccharide to an accep-
tor oligosaccharide and thus have the potential to undertake 
CS GAG polymerization. The designations of the enzymes 
involved in GAG polymerization have been evolving over 
the last decade so it is noted that the text of this manuscript 
utilizes the designations as used in the quoted references and 
Table 1.  Designation of the six human enzymes associated with chondroitin sulfate glycosaminoglycan chain polymerization. Note 
that an additional eight or more enzymes can be involved in the synthesis of GAG chains, some of which may impact of 
GAG elongation, but this table and paper focuses on those enzymes primarily involved in GAG chain polymerization 
Transferase/Polymerase Name
 1 EC  Number
2 Gene  Name References 
Chondroitin sulfate 
N-acetylgalactosaminyltransferase 1 
CGAT1 2.4.1.174  CSGALNACT1  [26,  27] 
Chondroitin sulfate 
N-acetylgalactosaminyltransferase 2 
CGAT2 2.4.1.174  CSGALNACT2  [53,  28] 
Chondroitin sulfate glucuronyltransferase CHGUT  2.4.1.226  CSGLCAT  [26] 
Chondroitin sulfate synthase 1  CHSS1  2.4.1.226 
2.4.1.175 
CHSY1 [24,  29] 
Chondroitin sulfate synthase 2  CHSS2  2.4.1.226 
2.4.1.175 
CHPF [29] 
Chondroitin sulfate synthase 3  CHSS3  2.4.1.226 
2.4.1.175 
CHSY3 [31] 
1Nomenclature of the UniProt Knowledgebase of ExPASy Proteomics server. 
2Transferase activities are: EC 2.4.1.174, EC 2.4.1.175 is N-acetylgalactosaminyltransferase (GalNAc transferase) activity; EC 2.4.1.226 is Glucuronyltransferase (GlcA transferase) 
activity. 138    The Open Biochemistry Journal, 2008, Volume 2  Little et al. 
these can be checked against the designations compiled in 
Table 1. Notably, although these enzymes act as monosac-
charide transferases, when expressed individually they do 
not manifest polymerase activity sufficient to generate GAG 
chains similar to those produced by intact cells. Recent ad-
vances described below, have revealed that the enzymes 
need to be expressed in combinations to achieve polymeriza-
tion activity. The genes for these enzymes are localized on 
different chromosomes despite significant homology in the 
nucleotide and amino acid sequences [31].  
  None of the individual enzymes possesses polymerase 
activity in vitro sufficient to produce a run of disaccharide 
repeat units that would constitute a GAG chain. ChSy-1 and 
ChPF show similar tissue distributions whereas ChSy-2 and 
ChSy-3 each show a specific tissue distribution which is 
distinct from the first mentioned pair of enzymes [32]. ChSy-
1, 2 and 3 along with ChPF have all been shown to colocal-
ise in the Golgi where they work in an orchestrated manner 
to manifest GAG polymerization [33]. It has emerged that 
some of these enzymes exhibit transferase and polymerase 
activity whereas some act as chaperones which bind to part-
ners to generate complexes which show polymerization ac-
tivity. Importantly, polymerization activity of the different 
combinations of glycosyltransferases and chaperones is vari-
able and so is the length of the resultant GAG chains which 
are synthesized by various different combinations of en-
zymes [32].  
 The  chondroitin glycosyltransferases, ChGn-1 and 
ChGn-2 (GalNAcT-1 and -2), are apparently not essential for 
CS GAG polymerization and notably homologues of these 
transferases are not present in Caenorhabditis elegans which 
does possess chondroitin GAGs [34]. It is unclear why so 
many CS synthesizing enzymes exist in nature. It is notable 
that no cell lines with greatly disrupted CS biosynthesis have 
been reported and this may be due to a high level of func-
tional redundancy that is conferred by having a family of 
polymerization enzymes available. The existence of multiple 
polymerizing enzymes, which when expressed in different 
relative abundances synthesize GAG chains of different 
lengths provides an explanation for the existence of variabil-
ity in the length of GAG chains occurring in different tis-
sues, at different developmental stages and in disease states 
[8, 35, 36]. Differential expression associated with varying 
GAG polymerizing activity also provides a possible mecha-
nism for the action of external stimuli to modify GAG length 
which could occur, for example, by alterations in the relative 
expression of the enzymes and chaperones. The implications 
for different GAG lengths in different tissues and in different 
physiological and pathological states is presently unknown. 
  Most glycosyltransferases contain a DXD motif which is 
critical for catalytic function possibly by modulation of the 
binding of UDP-sugars through the coordination of a diva-
lent cation [37, 38]. ChPF lacks the usual DXD motif charac-
teristic of Golgi resident enzymes which opens the possibil-
ity of a different role from the integral membrane enzymes 
including the possibility that it may be rate limiting and 
amenable to altered expression which can alter the length of 
GAG chains [29].  
  Kitagawa and colleagues [32] showed that ChPF when 
expressed alone does not show polymerization activity but 
when it is expressed with other enzymes it is capable of me-
diating chain polymerization. Furthermore, the size of the 
GAG chains is dependent upon the glycosyltransferase part-
ner. For example, when ChPF is co-expressed and partners 
with ChSy-1 the resultant GAG chains are longer than when 
it is coexpresssed with ChSy-2 [32].  
  Each of ChSy-1,2 and 3 contain one domain with glyco-
syltransferase activity and accordingly pairs of enzymes 
carry two functional domains. Kitagawa and colleagues also 
examined the effect of mutating out the glycosyltransferase 
activity of ChSy-3 whilst demonstrating that the resultant 
protein did interact with other glycosyltransferases [33]. 
When evaluated for polymerization activity it was found that 
in the ChSy-3:ChSy-1 complex both domains contributed 
equally to polymerization however for the ChSy2:ChSy-3 
complex the ChSy-3 contributed totally to the polymeriza-
tion activity and the ChSy-2 served only, but critically, as a 
chaperone [33]. 
  CS polymerization complexes also bind to the proteogly-
can core protein or an equivalent initiation protein and the 
nature of the core protein can determine the extent of GAG 
polymerization observed. Furthermore, CS GAG synthesis is 
initiated on xyloside derivatives [3, 39] and the nature of the 
hydrophobic aglycone of the xyloside derivative can deter-
mine both the type of GAG chain as well as the length of the 
resultant chains. Thus, the polymerizing activity of the vari-
ous transferase complexes is modulated by the interaction 
with the recognition sequence of the proteoglycan core pro-
tein or artificially by the nature of the hydrophobic aglycone 
of a xyloside derivative. 
  Enzymatic sulfation during synthesis of the GAG chain is 
suggested to play a role in determining ultimate GAG length. 
Sulfation proceeds with polymerization and specific sulfate 
groups have stimulatory or inhibitory effects on GalNAc and 
GlcA transfer [24, 40]. Early studies suggested that 4,6-O 
sulfation on GalNAc and 3-O-sulfation on GlcA residues at 
the non-reducing end might be involved in terminating po-
lymerization of CS GAG chains [41]. A deeper understand-
ing of the processes of CS GAG polymerization will almost 
certainly provide insights into the molecular mechanisms 
through which supplementary chain modifications such as 
sulfation modulate GAG length and may therefore reveal 
tissue specific effects which will inform considerations of 
function.  
  Protein:protein interactions are pH sensitive and the pH 
alters throughout the Golgi apparatus. The pH generally de-
creases along the secretory pathway within the Golgi with a 
variation of as much as 0.5 pH units [33]. Coexpression of 
pairs of ChSy-3, ChSy-1 and ChPF using 
GlcUA1-3GalO-NM as an acceptor generates GAGs of 
differing length and the length is dependent upon the pH of 
the assay [33]. Thus, the localization of the glycosyltrans-
ferases in the Golgi and the pH at the relevant position be-
comes another determinant of natural GAG length. 
  Thus, full polymerization activity requires a complex of 
at least two of the four critical polymerization enzymes 
(ChSy-1, -2, -3 and ChPF) and the resultant polymerization 
capacity is variable depending upon the entities that form the 
complexes and the core protein to which they direct their 
activity. In summary, it is possible to speculate that the fac-
tors that determine natural GAG length in tissues are the Chondroitin Sulfate Synthesis  The Open Biochemistry Journal, 2008, Volume 2    139 
specific and relative level of expression of the six or perhaps 
only four enzymes shown in Table 1 (i.e. requirement for 
transferase versus polymerase activity), the respective core 
protein, the pH of the Golgi subcompartments and the sul-
fation of the disaccharides in the forming GAG chain. 
5. MECHANISMS LEADING TO THE HYPERELON-
GATION OF CS GAG CHAINS  
  Cells synthesize CS proteoglycans with GAG chains of 
“natural” length due to the basal activity of the enzymes, 
transporters and processes associated with GAG biosynthesis 
in the cell, as described above. However, treatment of cells 
such as vascular smooth muscle cells (VSMC) with growth 
factors such as platelet-derived growth factor (PDGF), trans-
forming growth factor (TGF), angiotensin II and metabolic 
agents including oxLDL leads to the synthesis and secretion 
of CS/DS proteoglycans which are larger than those from 
untreated cells [3, 12, 42, 43]. For a specific example of the 
effect of treating cells with TGF on the size of the resultant 
proteoglycans see Fig. (1) (lower panel). Size increases of 
proteoglycans are due to elongation of the GAG chains 
which can be demonstrated by the chemical cleavage of the 
chains from the core proteins and GAG size analysis by 
SDS-PAGE, size exclusion chromatography or fluorophore 
assisted carbohydrate electrophoresis (FACE) [3, 44]. The 
increase in size of the GAG chains is approximately 10-20 
per cent [3]. Some growth factors such as PDGF also cause 
an increase in the 6-sulfation of the CS/DS GAG chain but 
others such as TGF only cause GAG elongation [45]. CS 
GAG chains may also be modified by epimerization which 
changes the sugars from GlcA to IdoA (and hence CS to DS 
GAG chains). Although this has the potential to modify the 
interaction with apolipoproteins little is known of the role of 
growth factors and other stimuli in regulating this reaction 
[18]. We have observed that GAGs secreted by cultured 
VSMCs have a particularly high CS versus DS content sug-
gesting that epimerase activity may be down regulated in 
such cultured cells (Little and Nigro, unpublished observa-
tion). 
  The signaling pathways downstream of receptor activa-
tion mediating GAG hyperelongation are complex and in 
some cases novel pathways appear to be involved. Using the 
example of VSMCs several growth factors including PDGF, 
TGF and thrombin have been shown to mediate GAG (hy-
per)elongation and the signaling pathways eliciting this re-
sponse have been partially characterized. Schonherr et al. [5] 
reported that PDGF stimulates GAG elongation of CS GAGs 
by monkey VSMCs however the response is not blocked by 
the isoflavone, genistein. Genistein, the prototypical inhibi-
tor of the intrinsic tyrosine kinase autotransphosphorylation 
activity of the dimeric PDGF receptor and is an inhibitor of 
PDGF-mediated mitogenic signaling in VSMC [5]. The data 
of Schonherr et al. [5] leads to the implication that there may 
be a PDGFR tyrosine kinase independent signal transduction 
pathway controlling GAG elongation. There is evidence for 
this in that PDGF-stimulated early growth response gene 
(egr)-1 expression in 3T3 fibroblasts cells is also not blocked 
by genistein [46]. 
  The action of TGF to stimulate CS/DS GAG elongation 
in human VSMCs involves the canonical Smad/phospho-
Smad 2/3 pathway but also has the novel aspect that it en-
gages the p38/phospho p38 Mitogen Activated Protein 
Kinase (MAPK) pathway usually associated with stress sig-
naling [13].  
  The action of the serine protease, thrombin to stimulate 
GAG elongation in VSMCs is mediated via  the Protease 
Activated Receptor-1 and involves protein kinase C and 
transactivation of the Epidermal Growth Factor receptor 
[47].  
  The precise biochemical mechanism(s) through which 
the signaling pathways activated by growth factors lead to 
hyperelongation of GAGs is unknown. ALK  V/Smad and 
p38 MAPK signaling pathways generate signaling interme-
diates which move to the nucleus and act as transcription 
factors. These transcription factors may for example alter the 
expression of the GAG polymerizing enzymes however stud-
ies of the regulation of GAG polymerizing enzymes have so 
far not yielded substantial advances [13, 48]. ChPF has re-
cently been discovered and shown to play a role in CS GAG 
polymerization in vitro [32]. Whether or not the growth fac-
tors may be regulating the expression and action of ChPF is 
an interesting question. ChSy-1 leads to longer GAG chains 
in vitro than ChSy-2 (when each is co expressed with ChPF) 
so one possibility is that hyperelongation may occur due to a 
shift in the major enzyme from ChSy-2 to ChSy-1. For ex-
ample, both enzymes may be involved in the synthesis of 
natural length GAG chains – leading to the spectrum of 
chain sizes observed – and growth factors may stimulate the 
expression of ChPF which is targeted within the cell at 
ChSy-1 thus yielding longer GAG chains.  
6. DIFFERENTIATING NATURAL GAG SYNTHESIS 
FROM GAG HYPERELONGATION 
  GAG formation is performed by a number of membrane 
bound enzymes located in the Golgi apparatus [18]. As dis-
cussed, a variety of agonists can stimulate elongation of 
GAG chains [3, 12, 42, 43]. The signaling pathways through 
which agonists mediate GAG elongation are being revealed 
and represent known and possibly novel pathways. It is un-
known how these signaling pathways mediate their effects to 
cause GAG elongation. An interesting question is whether or 
not natural GAG synthesis and agonist-mediated hyperelon-
gation involves the synthesis of new proteins? Vijayagopol 
and colleagues [49] showed that a growth factor mixture 
(conditioned media) derived from endothelial cells and con-
taining TGF stimulated an increase in the size of proteogly-
cans and thus by implication the size of the GAG chains 
produced by bovine aortic smooth muscle cells. The GAG 
elongation was blocked by cycloheximide which prevents 
de novo protein synthesis and also by the transcription in-
hibitor actinomycin  D [49]. We have recently confirmed 
some of these results in human VSMCs where cyclohexi-
mide inhibits PDGF mediated GAG elongation (Ballinger 
and Little, unpublished observations). The data that cyclo-
heximide inhibits growth factor mediated GAG elongation 
but not basal GAG synthesis, demonstrates that the synthesis 
of natural GAGs does not involve de novo protein synthesis 
(in the relatively short timeframe of the experiment) but the 
ability of growth factors to cause GAG hyperelongation is 
dependent upon de novo protein synthesis. There are several 
possible interpretations of these results. It is likely that the 
integral membrane enzymes mediating the synthesis of natu-140    The Open Biochemistry Journal, 2008, Volume 2  Little et al. 
ral GAGs have a slow turnover rate due to the more stable 
environment within the membranes of the Golgi apparatus. 
The Golgi resident enzyme galactosyltransferase in which 
the mature enzyme is phosphorylated has an average half life 
of about 19 hours [50, 51]. Although it is obvious that there 
must be some turnover and thus new synthesis of enzymes 
required for GAG synthesis it is possible that the need to 
replenish these enzymes as they are naturally degraded is 
very slow. Although the synthesis of natural GAGs on pro-
teoglycans does not require de novo protein synthesis the 
action of growth factors to hyperelongate GAGs is clearly 
dependent upon the synthesis of new protein. There are at 
least two possibilities for the role of this newly synthesized 
protein in mediating GAG elongation – either the signaling 
pathway linking receptor activation and GAG hyperelonga-
tion involves gene expression and new protein synthesis or 
the agonist is causing the increased expression and synthesis 
of a factor or cofactor which is rate limiting in GAG synthe-
sis [32]. For example, in the pathway that TGF stimulates 
biglycan expression in PANC-1 and MG-63 cells, the initial 
stimulation of Smad phosphorylation is followed by the ex-
pression and synthesis of GADD45 which activates p38 
MAPK [52]. This is a rapid response and it would be ex-
pected that acute cycloheximide treatment could block this 
pathway.  
  Thus, there appears to be a clear difference between natu-
ral GAG synthesis and GAG hyperelongation and a schema 
is shown in Fig. (2). The fact that GAG hyperelongation has 
very specific signaling pathways that involve de novo protein 
synthesis further validates GAG hyperelongation as a poten-
tial therapeutic target [14, 16, 17].  
7. CONCLUSIONS 
  Recent advances in the cloning and expression of CS 
glycosyltransferases have identified six functional enzymes, 
four of which appear to be the most important for CS GAG 
polymerization. These proteins work in combination, cer-
tainly at least in pairs, to manifest CS GAG polymerization 
to form tissue specific “natural” CS GAG polymers. The 
relative level of expression of the respective enzymes, the 
specific proteoglycan core protein, pH of the Golgi subcom-
partments and the activity of sulfotransferases are factors 
that determine natural GAG length. 
  Superimposed on this basic cell biology of CS GAG syn-
thesis are the external factors that have classic cell surface 
receptors and intracellular signaling pathways that can mod-
ify the ultimate GAG length most specifically leading to 
GAG elongation of the order of 20 percent. This GAG elon-
gation is functionally significant because it leads to enhanced 
binding to LDL which is closely associated with the earliest 
stages of the initiation of atherosclerosis [9, 14]. How the 
signaling pathways link to GAG elongation and whether or 
not this is due to an impact on natural GAG synthesis or the 
superimposition of a distinct process is presently unknown. 
This is an important question because if GAG hyperelonga-
tion can be separated from natural GAG synthesis then it 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Schema of the biochemical processes leading to the synthesis of natural chondroitin sulfate glycosaminoglycan (GAG) chains and 
the hyperelongation of GAG chains elicited by multiple cell signaling pathways resulting from the action of growth factor such as PDGF and 
TGF. ChSy chondroitin synthase; ChPF chondroitin polymerizing factor. The scheme to the left shows the normal biosynthesis of a proteo-
glycan core protein which is new protein and therefore cycloheximide sensitive but is also subject, based on individual and specific core 
proteins, to up regulation by growth factors. Various combinations, at least pairs of polymerases (see Table 1) add monosaccharides to the 
preformed tetrasaccharide linkage region on a serine residue on the core protein to produce the “natural” length glycosaminoglycan (GAG) 
chain. To the right of the scheme it is indicated that growth factors can intervene to result in the production of longer, so-called hyperelon-
gated GAG chains and although this is cycloheximide sensitive (see text) and acutely requires new protein synthesis the site at which the new 
protein synthesis occurs, either in the signaling pathway or in the actual transporters and enzymes that synthesis GAGs is unknown. The 
GAG elongation in response to growth factors is of the order of 20 per cent but this is sufficient to half the affinity of binding of the GAG 
chain to LDL. 
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may lead to identification of a therapeutic target which al-
lows for the prevention of disease without interfering with 
the physiological role of proteoglycans.  
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